A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo

Genetic engineering of T cells with a T cell receptor (TCR) targeting tumor antigen is a promising strategy for cancer immunotherapy. Inefficient expression of the introduced TCR due to TCR mispairing may limit the efficacy and adversely affect the safety of TCR gene therapy. Here, we evaluated the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Ther
Autori principali: Echchannaoui, Hakim, Petschenka, Jutta, Ferreira, Edite Antunes, Hauptrock, Beate, Lotz-Jenne, Carina, Voss, Ralf-Holger, Theobald, Matthias
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Gene & Cell Therapy 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319330/
https://ncbi.nlm.nih.gov/pubmed/30528087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2018.11.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi